Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

HHS bypassed normal procedures as it laid off thousands of employees, according to sources. One union has already filed an ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

Rare diseases, often referred to as orphan diseases, affect small patient populations, yet collectively they impact more than ...

The leaked budget draft, if approved by Congress, would reduce the FDA’s budget authority, indicating more disruption could ...